Chromadex Corp (CDXC) 1.3860 $CDXC
ChromaDex's (CDXC) CEO Frank Jaksch on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon May 18, 3:17PM CDT
ChromaDex to Present at the 2015 Marcum MicroCap Conference on May 28, 2015
GlobeNewswire - Mon May 18, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 2015 Marcum MicroCap Conference. The conference is being held on May 27 to 28, 2015 at The Grand Hyatt Hotel in New York City.
ChromaDex Reports 1st Quarter Record Revenue as Ingredients Sales Soar 136%
GlobeNewswire - Thu May 14, 3:45PM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today record revenue for the first quarter ended April 4, 2015. The report marks the fourth consecutive quarter of record revenues.
VBIV: 2.76 (+0.01)
ChromaDex to Host First Quarter 2015 Investor Call on Monday, May 18th at 11 am EDT
GlobeNewswire - Mon May 11, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, plans to report its first quarter 2015 financial results on Thursday, May 14, after the close of the financial markets.
Washington University Medical School Scientists Publish Results of Pre-Clinical Study Showing Nicotinamide Riboside is Effective in Rescuing Neurons Subjected to Trauma and Disease
GlobeNewswire - Wed Apr 29, 5:30AM CDT
- Study Showed Axon Degeneration and Cell Death are Blocked by Supplementation with the Cell-permeable NAD+ Precursor, Nicotinamide Riboside -
ChromaDex Appoints Former GlaxoSmithKline Executive, Jeff Baxter, to Its Board of Directors
GlobeNewswire - Mon Apr 20, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that Jeff Baxter has joined the Company's Board of Directors as an Independent Director.
IMDZ: 22.78 (+1.67), VBIV: 2.76 (+0.01), GSK: 44.66 (-0.11)
Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage and Carcinogenesis
GlobeNewswire - Fri Apr 10, 5:30AM CDT
A study recently published on April 3, 2015 in Free Radical Biology and Medicine showed pterostilbene prevented acute ultraviolet B radiation ("UVB"
, radiation-induced inflammation and photoaging-associated skin damages. The study further showed that pterostilbene, but not resveratrol, effectively prevented chronic UVB radiation-induced skin carcinogenesis (90% of pterostilbene-treated mice did not develop skin carcinomas, whereas a large number of tumors was observed in all controls). The anticarcinogenic effect elicited by pterostilbene was associated with maintenance of skin antioxidant defenses and inhibition of UVB-induced oxidative damage.
ChromaDex incurs higher net loss of USD5.4m in 2014
M2 - Fri Mar 20, 7:00AM CDT
Natural products company ChromaDex (Other OTC:CDXC) stated on Thursday that it recorded a net loss of USD5.4m (USD0.05 per common share) for the year ended 3 January 2015 (FY 2014).
ChromaDex® Reports 2014 Ingredient Sales Grew 182%
PR Newswire - Thu Mar 19, 5:35AM CDT
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the financial results for the year ended January 3, 2015.
ChromaDex® Appoints Former Nestle Executive, Steve Allen, as Chairman
PR Newswire - Tue Mar 03, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the appointment of Steve Allen as the Chairman of its Board. Allen, age 65, joined the Company's Board as an independent director in January 2014.
ChromaDex® to Present at the 27th Annual ROTH Conference on March 10, 2015
PR Newswire - Wed Feb 18, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 27th Annual ROTH Conference. The conference is being held on March 8-11, 2015 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
Sports Nutrition Supplier BPI Sports Adopts ChromaDex® Quality Verification Seal Program
PR Newswire - Thu Feb 05, 5:25AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that sports nutrition supplier BPI Sports has contracted with ChromaDex for third-party verification of BPI Sports' protein products.
ChromaDex® CEO to Present at The Sidoti & Company, LLC Emerging Growth Institutional Investor Forum on January 12th
PR Newswire - Tue Jan 06, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Sidoti & Company, LLC's Emerging Growth Institutional Investor Forum on Monday, Jan. 12, 2015 at The Grand Hyatt Hotel in New York City.
NIH Publishes Results of Preclinical Collaboration with ChromaDex Showing Potential Benefit of Nicotinamide Riboside
PR Newswire - Wed Dec 10, 5:30AM CST
ChromaDex Corp. (OTCQX: CDXC), announced today that the results of a mouse study performed in collaboration with ChromaDex by the National Institute on Aging (NIA), a member of the National Institutes of Health (NIH), were published in Cell Metabolism in November 2014. The results indicated that nicotinamide riboside (NR) was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a devastating accelerated aging disease known as Cockayne Syndrome (CS). The researchers concluded that NR showed promise as a potential therapy for the disease, as well as for other age-related neurodegenerative conditions. ChromaDex is an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.
NeutriSci Commences Trading and Provides Corporate Update
Marketwired - Thu Dec 04, 1:12PM CST
NeutriSci International Inc. (the "Company" or "NeutriSci" (TSX VENTURE: NU) is pleased to announce that it has commenced trading as a Tier 2 TSX-V issuer under the symbol NU.
NU.VN: 0.320 (+0.010)
ChromaDex announces USD750,000 cash from sale of its BluScience Line
M2 - Thu Dec 04, 5:30AM CST
Natural products company ChromaDex (Other OTC:CDXC) reported on Wednesday the receipt of approximately USD750,000 in cash in connection with the prior sale of its BluScience line to NeutriSci International.
ChromaDex® CEO to Present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Dec. 11
PR Newswire - Thu Dec 04, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Thursday, Dec. 11, 2014, located at the Palmer House Hilton in Chicago.
ChromaDex paid for NeutriSci shares
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 7:36AM CST
ChromaDex® Receives $750,000 Cash from Previous Sale of its BluScience(TM) Line
PR Newswire - Wed Dec 03, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has received a cash payment of approximately $750,000 for the shares of NeutriSci International Inc. ("NeutriSci", that the company received as part of its prior transaction with NeutriSci.
ChromaDex's (CDXC) CEO Frank Jaksch on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon May 18, 3:17PM CDT
ChromaDex to Present at the 2015 Marcum MicroCap Conference on May 28, 2015
GlobeNewswire - Mon May 18, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 2015 Marcum MicroCap Conference. The conference is being held on May 27 to 28, 2015 at The Grand Hyatt Hotel in New York City.
ChromaDex Reports 1st Quarter Record Revenue as Ingredients Sales Soar 136%
GlobeNewswire - Thu May 14, 3:45PM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today record revenue for the first quarter ended April 4, 2015. The report marks the fourth consecutive quarter of record revenues.
VBIV: 2.76 (+0.01)
ChromaDex to Host First Quarter 2015 Investor Call on Monday, May 18th at 11 am EDT
GlobeNewswire - Mon May 11, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, plans to report its first quarter 2015 financial results on Thursday, May 14, after the close of the financial markets.
Washington University Medical School Scientists Publish Results of Pre-Clinical Study Showing Nicotinamide Riboside is Effective in Rescuing Neurons Subjected to Trauma and Disease
GlobeNewswire - Wed Apr 29, 5:30AM CDT
- Study Showed Axon Degeneration and Cell Death are Blocked by Supplementation with the Cell-permeable NAD+ Precursor, Nicotinamide Riboside -
ChromaDex Appoints Former GlaxoSmithKline Executive, Jeff Baxter, to Its Board of Directors
GlobeNewswire - Mon Apr 20, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that Jeff Baxter has joined the Company's Board of Directors as an Independent Director.
IMDZ: 22.78 (+1.67), VBIV: 2.76 (+0.01), GSK: 44.66 (-0.11)
Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage and Carcinogenesis
GlobeNewswire - Fri Apr 10, 5:30AM CDT
A study recently published on April 3, 2015 in Free Radical Biology and Medicine showed pterostilbene prevented acute ultraviolet B radiation ("UVB"
, radiation-induced inflammation and photoaging-associated skin damages. The study further showed that pterostilbene, but not resveratrol, effectively prevented chronic UVB radiation-induced skin carcinogenesis (90% of pterostilbene-treated mice did not develop skin carcinomas, whereas a large number of tumors was observed in all controls). The anticarcinogenic effect elicited by pterostilbene was associated with maintenance of skin antioxidant defenses and inhibition of UVB-induced oxidative damage. ChromaDex incurs higher net loss of USD5.4m in 2014
M2 - Fri Mar 20, 7:00AM CDT
Natural products company ChromaDex (Other OTC:CDXC) stated on Thursday that it recorded a net loss of USD5.4m (USD0.05 per common share) for the year ended 3 January 2015 (FY 2014).
ChromaDex® Reports 2014 Ingredient Sales Grew 182%
PR Newswire - Thu Mar 19, 5:35AM CDT
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the financial results for the year ended January 3, 2015.
ChromaDex® Appoints Former Nestle Executive, Steve Allen, as Chairman
PR Newswire - Tue Mar 03, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the appointment of Steve Allen as the Chairman of its Board. Allen, age 65, joined the Company's Board as an independent director in January 2014.
ChromaDex® to Present at the 27th Annual ROTH Conference on March 10, 2015
PR Newswire - Wed Feb 18, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 27th Annual ROTH Conference. The conference is being held on March 8-11, 2015 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
Sports Nutrition Supplier BPI Sports Adopts ChromaDex® Quality Verification Seal Program
PR Newswire - Thu Feb 05, 5:25AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that sports nutrition supplier BPI Sports has contracted with ChromaDex for third-party verification of BPI Sports' protein products.
ChromaDex® CEO to Present at The Sidoti & Company, LLC Emerging Growth Institutional Investor Forum on January 12th
PR Newswire - Tue Jan 06, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Sidoti & Company, LLC's Emerging Growth Institutional Investor Forum on Monday, Jan. 12, 2015 at The Grand Hyatt Hotel in New York City.
NIH Publishes Results of Preclinical Collaboration with ChromaDex Showing Potential Benefit of Nicotinamide Riboside
PR Newswire - Wed Dec 10, 5:30AM CST
ChromaDex Corp. (OTCQX: CDXC), announced today that the results of a mouse study performed in collaboration with ChromaDex by the National Institute on Aging (NIA), a member of the National Institutes of Health (NIH), were published in Cell Metabolism in November 2014. The results indicated that nicotinamide riboside (NR) was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a devastating accelerated aging disease known as Cockayne Syndrome (CS). The researchers concluded that NR showed promise as a potential therapy for the disease, as well as for other age-related neurodegenerative conditions. ChromaDex is an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.
NeutriSci Commences Trading and Provides Corporate Update
Marketwired - Thu Dec 04, 1:12PM CST
NeutriSci International Inc. (the "Company" or "NeutriSci"
(TSX VENTURE: NU) is pleased to announce that it has commenced trading as a Tier 2 TSX-V issuer under the symbol NU. NU.VN: 0.320 (+0.010)
ChromaDex announces USD750,000 cash from sale of its BluScience Line
M2 - Thu Dec 04, 5:30AM CST
Natural products company ChromaDex (Other OTC:CDXC) reported on Wednesday the receipt of approximately USD750,000 in cash in connection with the prior sale of its BluScience line to NeutriSci International.
ChromaDex® CEO to Present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Dec. 11
PR Newswire - Thu Dec 04, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Thursday, Dec. 11, 2014, located at the Palmer House Hilton in Chicago.
ChromaDex paid for NeutriSci shares
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 7:36AM CST
ChromaDex® Receives $750,000 Cash from Previous Sale of its BluScience(TM) Line
PR Newswire - Wed Dec 03, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has received a cash payment of approximately $750,000 for the shares of NeutriSci International Inc. ("NeutriSci"
, that the company received as part of its prior transaction with NeutriSci. 
